Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study

JD. Doecke, G. Bellomo, L. Vermunt, D. Alcolea, S. Halbgebauer, S. In 't Veld, N. Mattsson-Carlgren, K. Veverova, CJ. Fowler, L. Boonkamp, IM. Houtkamp, M. Koel-Simmerlink, IMW. Verberk, L. Gaetani, A. Toja, AL. Wojdała, J. Fortea, Y. Pijnenburg,...

. 2025 ; 21 (6) : e14573. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015394

Grantová podpora
ADG-101096455 European Research Council - International
GHR Foundation
2022-00775 Swedish Research Council
ERAPERMED2021-184 ERA PerMed
2022-0231 Knut and Alice Wallenberg foundation
Strategic Research Area MultiPark
Lund University
AF-980907 Swedish Alzheimer Foundation
FO2021-0293 Swedish Brain Foundation
1412/22 Parkinson foundation of Sweden
Cure Alzheimer's fund
Rönström Family Foundation
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
2020-O000028 Skåne University Hospital Foundation
2022-1259 Regionalt Forskningsstöd
2022-Projekt0080 Regionalt Forskningsstöd
TriBEKa-17-519007 LCF/PR/GN17/50300004
SGR 00913 LCF/PR/GN17/50300004
European Commission
Marie Curie International Training Network)
Innovative Medicines Initiatives 3TR
European Union's Horizon Europe Research
Innovation Programme
Alzheimer Association
Health Holland
Dutch Research Council - Netherlands
Alzheimer Drug Discovery Foundation
The Selfridges Group Foundation
Alzheimer Netherlands
Dutch National Dementia Strategy

INTRODUCTION: Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aβ42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we assess which markers can best identify AD from controls and other non-AD dementias in a large international multi-center study. METHODS: Plasma samples (n = 1298) were collected from six international centers. Aβ40, Aβ42, GFAP, NfL, and p-tau181 were measured using single molecule array. In each group, AD diagnosis/co-pathology was defined according to cerebrospinal fluid biomarkers or amyloid positron emission tomography. Validations were performed in three separate cohorts via single and dual cut-off models. RESULTS: p-tau181 showed the best area under the curve value to separate AD from frontotemporal dementia, controls, and Aβ- dementia with Lewy bodies. However, this discriminative power could not be reproduced by applying pre-defined cut-offs. DISCUSSION: p-tau181 was the best single plasma marker for detecting AD at any stage. Specific cut-offs are needed to maximize diagnostic performances. HIGHLIGHTS: Phosphorylated tau (p-tau)181 provided a clear differentiation between controls and Alzheimer's disease (AD) participants, with evidence of increased levels in the preclinical stage of AD. Plasma biomarkers demonstrated that when amyloid co-pathology is removed from dementia with Lewy bodies (DLB), only glial fibrillary acidic protein and neurofilament light chain remain to predict DLB. Given the low prevalence of amyloid co-pathology in frontotemporal dementia (FTD), p-tau181 and its ratio with amyloid beta 42 are strong biomarkers to differentiate FTD from AD.

Alzheimer Center Amsterdam Department of Neurology Amsterdam Neuroscience Amsterdam University Medical Centers Amsterdam the Netherlands

Australian E Health Research Centre CSIRO Herston Queensland Australia

Barcelonaβeta Brain Research Center Pasqual Maragall Foundation Sant Martí Barcelona Spain

Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable Instituto de Salud Carlos 3 Madrid Spain

Clinical Memory Research Unit Department of Clinical Sciences Malmö Faculty of Medicine Lund University Lund Sweden

Cognitive and Behavioural Neurology Unit Department of Neurology Hospital del Mar Ciutat Vella Barcelona Spain

Departamento de Ciencias Farmacéuticas y de la Salud Facultad de Farmacia Universidad San Pablo CEU CEU Universities Urbanización Montepríncipe Fuencarral El Pardo Spain

Department of Neurology Hospital del Mar Research Institute Ciutat Vella Barcelona Spain

Department of Neurology Institut d'Investigacions Biomèdiques Sant Pau Hospital de Sant Pau Universitat Autònoma de Barcelona Hospital de la Santa Creu i Sant Pau Barcelona Spain

Department of Neurology University of Ulm Ulm Germany

Faculty of Medicine and Life Sciences Universitat Pompeu Fabra Carrer de la Mercè Ciutat Vella Barcelona Spain

Memory Clinic Department of Neurology Charles University 2nd Faculty of Medicine and Motol University Hospital Prague Czech Republic

Memory Clinic Skåne University Hospital Malmö Sweden

Neurochemistry Laboratory Department of Laboratory Medicine Amsterdam Neuroscience Amsterdam University Medical Center Vrije Universiteit Amsterdam the Netherlands

Neurology Clinic Skåne University Hospital Malmö Sweden

Section of Neurology Laboratory of Clinical Neurochemistry Department of Medicine and Surgery University of Perugia Perugia Italy

The University of Melbourne The Florey Institute Victoria Melbourne Australia

Translational AI in Laboratory Medicine Department of Laboratory Medicine Location VUmc Amsterdam the Netherlands

Wallenberg Center for Molecular Medicine Lund University Lund Sweden

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015394
003      
CZ-PrNML
005      
20250731090943.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/alz.14573 $2 doi
035    __
$a (PubMed)40551285
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Doecke, James D $u Australian E-Health Research Centre, CSIRO, Herston, Queensland, Australia $1 https://orcid.org/0000000328630293
245    10
$a Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study / $c JD. Doecke, G. Bellomo, L. Vermunt, D. Alcolea, S. Halbgebauer, S. In 't Veld, N. Mattsson-Carlgren, K. Veverova, CJ. Fowler, L. Boonkamp, IM. Houtkamp, M. Koel-Simmerlink, IMW. Verberk, L. Gaetani, A. Toja, AL. Wojdała, J. Fortea, Y. Pijnenburg, A. Lemstra, W. van der Flier, J. Hort, M. Otto, O. Hansson, L. Parnetti, CL. Masters, A. Lleó, A. González-Escalante, J. Contador, M. Suárez-Calvet, A. Fernández-Lebrero, A. Puig-Pijoan, P. Ortiz-Romero, E. Jiménez-Moyano, C. Minguillón, M. Del Campo, C. Teunissen
520    9_
$a INTRODUCTION: Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aβ42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we assess which markers can best identify AD from controls and other non-AD dementias in a large international multi-center study. METHODS: Plasma samples (n = 1298) were collected from six international centers. Aβ40, Aβ42, GFAP, NfL, and p-tau181 were measured using single molecule array. In each group, AD diagnosis/co-pathology was defined according to cerebrospinal fluid biomarkers or amyloid positron emission tomography. Validations were performed in three separate cohorts via single and dual cut-off models. RESULTS: p-tau181 showed the best area under the curve value to separate AD from frontotemporal dementia, controls, and Aβ- dementia with Lewy bodies. However, this discriminative power could not be reproduced by applying pre-defined cut-offs. DISCUSSION: p-tau181 was the best single plasma marker for detecting AD at any stage. Specific cut-offs are needed to maximize diagnostic performances. HIGHLIGHTS: Phosphorylated tau (p-tau)181 provided a clear differentiation between controls and Alzheimer's disease (AD) participants, with evidence of increased levels in the preclinical stage of AD. Plasma biomarkers demonstrated that when amyloid co-pathology is removed from dementia with Lewy bodies (DLB), only glial fibrillary acidic protein and neurofilament light chain remain to predict DLB. Given the low prevalence of amyloid co-pathology in frontotemporal dementia (FTD), p-tau181 and its ratio with amyloid beta 42 are strong biomarkers to differentiate FTD from AD.
650    _2
$a lidé $7 D006801
650    12
$a proteiny tau $x krev $7 D016875
650    12
$a amyloidní beta-protein $x krev $7 D016229
650    12
$a Alzheimerova nemoc $x krev $x diagnóza $7 D000544
650    12
$a neurofilamentové proteiny $x krev $7 D016900
650    12
$a gliový fibrilární kyselý protein $x krev $7 D005904
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a senioři $7 D000368
650    12
$a peptidové fragmenty $x krev $7 D010446
650    _2
$a fosforylace $7 D010766
650    12
$a demence $x krev $x diagnóza $7 D003704
650    _2
$a lidé středního věku $7 D008875
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Bellomo, Giovanni $u Section of Neurology, Laboratory of Clinical Neurochemistry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
700    1_
$a Vermunt, Lisa $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, the Netherlands $u Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Amsterdam, the Netherlands
700    1_
$a Alcolea, Daniel $u Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
700    1_
$a Halbgebauer, Steffen $u Department of Neurology, University of Ulm, Ulm, Germany
700    1_
$a In 't Veld, Sjors $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, the Netherlands $u Translational AI in Laboratory Medicine, Department of Laboratory Medicine, Location VUmc, Amsterdam, the Netherlands
700    1_
$a Mattsson-Carlgren, Niklas $u Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden $u Neurology Clinic, Skåne University Hospital, Malmö, Sweden $u Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden
700    1_
$a Veverova, Katerina $u Memory Clinic, Department of Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
700    1_
$a Fowler, Christopher J $u The University of Melbourne, The Florey Institute, Victoria, Melbourne, Australia
700    1_
$a Boonkamp, Lynn $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, the Netherlands
700    1_
$a Houtkamp, Isabel M $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, the Netherlands $u Translational AI in Laboratory Medicine, Department of Laboratory Medicine, Location VUmc, Amsterdam, the Netherlands
700    1_
$a Koel-Simmerlink, Marleen $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, the Netherlands
700    1_
$a Verberk, Inge M W $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, the Netherlands
700    1_
$a Gaetani, Lorenzo $u Section of Neurology, Laboratory of Clinical Neurochemistry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
700    1_
$a Toja, Andrea $u Section of Neurology, Laboratory of Clinical Neurochemistry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
700    1_
$a Wojdała, Anna Lidia $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, the Netherlands
700    1_
$a Fortea, Juan $u Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
700    1_
$a Pijnenburg, Yolande $u Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Amsterdam, the Netherlands
700    1_
$a Lemstra, Afina $u Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Amsterdam, the Netherlands
700    1_
$a van der Flier, Wiesje $u Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Centers, Amsterdam, the Netherlands
700    1_
$a Hort, Jakub $u Memory Clinic, Department of Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
700    1_
$a Otto, Markus $u Department of Neurology, University of Ulm, Ulm, Germany
700    1_
$a Hansson, Oskar $u Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden $u Memory Clinic, Skåne University Hospital, Malmö, Sweden
700    1_
$a Parnetti, Lucilla $u Section of Neurology, Laboratory of Clinical Neurochemistry, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
700    1_
$a Masters, Colin L $u The University of Melbourne, The Florey Institute, Victoria, Melbourne, Australia
700    1_
$a Lleó, Alberto $u Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
700    1_
$a González-Escalante, Armand $u Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Sant Martí, Barcelona, Spain $u Department of Neurology, Hospital del Mar Research Institute, Ciutat Vella, Barcelona, Spain $u Faculty of Medicine and Life Sciences, Universitat Pompeu Fabra, Carrer de la Mercè, Ciutat Vella, Barcelona, Spain
700    1_
$a Contador, José $u Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Sant Martí, Barcelona, Spain $u Department of Neurology, Hospital del Mar Research Institute, Ciutat Vella, Barcelona, Spain $u Cognitive and Behavioural Neurology Unit, Department of Neurology, Hospital del Mar, Ciutat Vella, Barcelona, Spain
700    1_
$a Suárez-Calvet, Marc $u Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Sant Martí, Barcelona, Spain $u Department of Neurology, Hospital del Mar Research Institute, Ciutat Vella, Barcelona, Spain $u Faculty of Medicine and Life Sciences, Universitat Pompeu Fabra, Carrer de la Mercè, Ciutat Vella, Barcelona, Spain $u Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain
700    1_
$a Fernández-Lebrero, Aida $u Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Sant Martí, Barcelona, Spain $u Department of Neurology, Hospital del Mar Research Institute, Ciutat Vella, Barcelona, Spain $u Faculty of Medicine and Life Sciences, Universitat Pompeu Fabra, Carrer de la Mercè, Ciutat Vella, Barcelona, Spain
700    1_
$a Puig-Pijoan, Albert $u Department of Neurology, Hospital del Mar Research Institute, Ciutat Vella, Barcelona, Spain $u Faculty of Medicine and Life Sciences, Universitat Pompeu Fabra, Carrer de la Mercè, Ciutat Vella, Barcelona, Spain
700    1_
$a Ortiz-Romero, Paula $u Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Sant Martí, Barcelona, Spain $u Department of Neurology, Hospital del Mar Research Institute, Ciutat Vella, Barcelona, Spain
700    1_
$a Jiménez-Moyano, Esther $u Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Sant Martí, Barcelona, Spain $u Department of Neurology, Hospital del Mar Research Institute, Ciutat Vella, Barcelona, Spain
700    1_
$a Minguillón, Carolina $u Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Sant Martí, Barcelona, Spain $u Department of Neurology, Hospital del Mar Research Institute, Ciutat Vella, Barcelona, Spain $u Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain $u Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Fuencarral-El Pardo, Spain
700    1_
$a Del Campo, Marta $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, the Netherlands $u Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Sant Martí, Barcelona, Spain $u Department of Neurology, Hospital del Mar Research Institute, Ciutat Vella, Barcelona, Spain $u Cognitive and Behavioural Neurology Unit, Department of Neurology, Hospital del Mar, Ciutat Vella, Barcelona, Spain
700    1_
$a Teunissen, Charlotte $u Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, the Netherlands $1 https://orcid.org/0000000240610837
773    0_
$w MED00166531 $t Alzheimer's & dementia $x 1552-5279 $g Roč. 21, č. 6 (2025), s. e14573
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40551285 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090937 $b ABA008
999    __
$a ok $b bmc $g 2366310 $s 1252519
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 21 $c 6 $d e14573 $e - $i 1552-5279 $m Alzheimer's & dementia $n Alzheimers Dement $x MED00166531
GRA    __
$a ADG-101096455 $p European Research Council $2 International
GRA    __
$p GHR Foundation
GRA    __
$a 2022-00775 $p Swedish Research Council
GRA    __
$a ERAPERMED2021-184 $p ERA PerMed
GRA    __
$a 2022-0231 $p Knut and Alice Wallenberg foundation
GRA    __
$p Strategic Research Area MultiPark
GRA    __
$p Lund University
GRA    __
$a AF-980907 $p Swedish Alzheimer Foundation
GRA    __
$a FO2021-0293 $p Swedish Brain Foundation
GRA    __
$a 1412/22 $p Parkinson foundation of Sweden
GRA    __
$p Cure Alzheimer's fund
GRA    __
$p Rönström Family Foundation
GRA    __
$p Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
GRA    __
$a 2020-O000028 $p Skåne University Hospital Foundation
GRA    __
$a 2022-1259 $p Regionalt Forskningsstöd
GRA    __
$a 2022-Projekt0080 $p Regionalt Forskningsstöd
GRA    __
$a TriBEKa-17-519007 $p LCF/PR/GN17/50300004
GRA    __
$a SGR 00913 $p LCF/PR/GN17/50300004
GRA    __
$p European Commission
GRA    __
$p Marie Curie International Training Network)
GRA    __
$p Innovative Medicines Initiatives 3TR
GRA    __
$p European Union's Horizon Europe Research
GRA    __
$p Innovation Programme
GRA    __
$p Alzheimer Association
GRA    __
$p Health Holland
GRA    __
$p Dutch Research Council $2 Netherlands
GRA    __
$p Alzheimer Drug Discovery Foundation
GRA    __
$p The Selfridges Group Foundation
GRA    __
$p Alzheimer Netherlands
GRA    __
$p Dutch National Dementia Strategy
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace